Кардиоваскулярная патология при спондилоартритах (обзор литературы)

   Спондилоартриты – группа заболеваний с поражением осевого скелета и крестцово-подвздошных суставов, включающая аксиальный спондилоартрит, или анкилозирующий спондилит, и периферический спондилоартрит. Спондилоартриты ассоциированы с увеличением сердечно-сосудистой заболеваемости и смертности, которая может быть результатом кардиальных проявлений болезни или обусловлена ускоренным развитием атеросклероза. Сочетание двух патологий способствует более тяжелому течению заболеваний и негативно влияет на результаты терапии, что свидетельствует об актуальности этой междисциплинарной проблемы. В обзоре освещены данные о сердечно-сосудистой заболеваемости и смертности при спондилоартритах, встречаемости различных факторов риска. Приведены данные о взаимосвязи кардиоваскулярной патологии с активностью и функциональными нарушениями при спондилоартритах.

1. Bosch P., Zhao S. S., Nikiphorou E. The association between comorbidities and disease activity in spondyloarthritis – a narrative review. Best Pract. Res. Clin. Rheumatol. 2023; 37 (3): 101857. doi: 10.1016/j.berh.2023.101857

2. Dey M., Nagy G., Nikiphorou E. Comorbidities or extra-articular manifestations: time to reconsider the terminology? Rheumatology. 2022; 61 (10): 3881e3. doi: 10.1093/rheumatology/keac134

3. Gupta S., Syrimi Z., Hughes D. M. et al. Comorbidities in psoriatic arthritis : a systematic review and meta-analysis. Rheumatol. Int. 2021; 41 (2): 275e84. doi: 10.1007/s00296-020-04775-2

4. Zhao S. S., Robertson S., Reich T. et al. Prevalence and impact of comorbidities in axial spondyloarthritis : systematic review and meta-analysis. Rheumatology. 2020; 59: iv47e57. doi: 10.1093/rheumatology/keaa246

5. Bhattad P., Kulkarni M., Patel P. D. et al. Cardiovascular morbidity in ankylosing spondylitis: a focus on inflammatory cardiac disease. Cureus. 2022; 14 (6): e25633. doi: 10.7759/cureus.25633

6. Kim J. H., Choi I. A. Cardiovascular morbidity, and mortality in patients with spondylarthritis: a meta-analysis. Int. J. Rheum. Dis. 2020; 24 (4): 477–486. doi: 10.1111/1756-185X.13970

7. Ягода А. В., Гладких Н. Н. Эндокард и клапаны сердца при системных ревматических болезнях. Ставрополь: Изд-во СтГМУ; 2021: 384.

8. Lai Y., Zhang Y., Mo S. et al. Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study. Ann. Rheum. Dis. 2022; 81: e43. doi: 10.1136/annrheumdis-2020-217313

9. Redeker I., Callhoff J., Hoffmann F. et al. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res. Ther. 2020; 22 (1): 210. doi: 10.1186/s13075-020-02301-0

10. Gökşenoğlu G., Buğdaycı D., Paker N. et al. The prevalence of comorbidity and predictors in ankylosing spondylitis. Turk. J. Phys. Med. Rehabil. 2019; 65 (2): 132–138. doi: 10.5606/tftrd.2019.2822

11. Годзенко А. А., Корсакова Ю. О., Румянцева О. А. и др. Прогрессирование патологии аорты и клапанов сердца у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2017; 55 (5): 509–513. doi: 10.14412/1995-4484-2017-509-513

12. Longo B., Kirchner L. A., Simioni J. et al. Electrocardiographic changes in spondyloarthritis and use of anti-TNF-α drugs: a retrospective study with 100 patients. Einstein (Sao Paulo). 2019; 17: eAO4539. doi: 10.31744/einstein_journal/2019AO4539

13. Bengtsson K., Klingberg E., Deminger A. et al. Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open. 2019; 5: e001053. doi: 10.1136/rmdopen-2019-001053

14. Сay H. F., Alkan Melikoğlu M., Yurdakul F. G. et al. Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar. Arch. Rheumatol. 2023; 38 (3): 333–346. doi: 10.46497/ArchRheumatol.2023.9793

15. Llop M., Gratacуs J., Moreno M. et al. Sex differential impact of comorbidities in spondyloarthritis: data from COMOSPA study. RMD Open. 2024; 10: e003776. doi: 10.1136/rmdopen-2023-003776

16. Bengtsson K., Forsblad-d’Elia H., Lie E. et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res. Ther. 2017; 19: 102. doi: 10.1186/s13075-017-1315-z

17. Eriksson J. K., Jacobsson L., Bengtsson K. et al. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann. Rheum. Dis. 2017; 76 (2): 364–370. doi: 10.1136/annrheumdis-2016-209315

18. Саидов Ё. У., Одилзода И. Ё., Хасанзода С. М. и др. Распространенность традиционных факторов риска развития сердечно-сосудистых осложнений у пациентов с ревматоидным и псориатическим артритом. Научно-практическая ревматология. 2020; 58 (2): 165–170. doi: 10.14412/1995-4484-2020-165-170

19. Moltó A., Nikiphorou E. Comorbidities in spondyloarthritis. Front. Med. 2018; 5: 62. doi: 10.3389/fmed.2018.00062

20. Rueda-Gotor J., Llorca J., Corrales A. et al. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clin. Exp. Rheumatol. 2016; 34: 885–892.

21. López-Medina C., Molto A. Comorbidity management in spondyloarthritis. RMD Open. 2020; 6: e001135. doi: 10.1136/rmdopen-2019-001135

22. Arévalo M., López-Medina C., Moreno Martinez-Losa M. et al. Role of HLA-B 27 in the comorbidities observed in axial spondyloarthritis: data from COMOSPA. Joint Bone Spine. 2020; 87 (5): 445–448. doi: 10.1016/j.jbspin.2020.03.012

23. Walsh J. A., Song X., Kim G., Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J. Pharm. Health. Serv. Res. 2018; 9 (2): 115–121. doi: 10.1111/jphs.12212

24. Exarchou S., Lie E., Lindström U. et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann. Rheum. Dis. 2016; 75: 1466–1472. doi: 10.1136/annrheumdis-2015-207688

25. Kerola A. M., Kazemi A., Rollefstad S. et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology. 2022; 61 (12): 4656e66. doi: 10.1093/rheumatology/keac210

26. Turina M. C., Yeremenko N., van Gaalen F. et al. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open. 2017; 3: e000319. doi: 10.1136/rmdopen-2016-000319

27. Skov L., Thomsen S. F., Kristensen L. E. et al. Cause-specific mortality in patients with psoriasis and psoriatic arthritis. Br. J. Dermatol. 2019; 180 (1): 100e7. doi: 10.1111/bjd.16919

28. van der Heijde D., Wei J. C., Dougados M. et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018; 392: 2441–451. doi: 10.1016/S0140-6736(18)31946-9

29. Баткаева Н. В., Коротаева Т. В., Баткаев Э. А. Структура кардиоваскулярной коморбидности у больных с тяжелыми формами псориаза: данные ретроспективного анализа госпитальной когорты. Научно-практическая ревматология. 2017; 55 (5): 493–499.

30. Derakhshan M. H., Goodson N. J., Packham J. C. et al. Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. J. Rheumatol. 2019; 46 (7): 701–709. doi: 10.3899/jrheum.180538

31. Liew J. W., Ward M. M., Reveille J. D. et al. Nonsteroidal antiinflammatory drug use and association with incident hypertension in ankylosing spondylitis. Arthritis Care Res. 2020; 72 (11): 1645e52. doi: 10.1002/acr.24070

32. Tibuakuu M., Kamimura D., Kianoush S. et al. The association between cigarette smoking and inflammation: the Genetic Epidemiology Network of Arteriopathy (GENOA) study. PLoS One. 2017; 12: e0184914. doi: 10.1371/journal.pone.0184914

33. Gisondi P., Fostini A. C., Fossà I. et al. Psoriasis and the metabolic syndrome. Clin. Dermatol. 2018; 36 (1): 21–28. doi: 10.1016/j.clindermatol.2017.09.005

34. Wibetoe G., Ikdahl E., Rollefstad S. et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res. Ther. 2017; 19: 153. doi: 10.1186/s13075-017-1358-1

35. Gkolfinopoulou C., Stratikos E., Theofilatos D. et al. Impaired antiatherogenic functions of high-density lipoprotein in patients with ankylosing spondylitis. J. Rheumatol. 2015; 42: 1652–1660. doi: 10.3899/jrheum.141532

36. van der Heijde D., Ramiro S., Landewé R. et al. 2016 update of the ASAS-EULAR management recom-mendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76 (6): 978–991. doi: 10.1136/annrheumdis-2016-210770

37. Genre F., Rueda-Gotor J., Quevedo-Abeledo J.C. et al. Insulin resistance in non-diabetes patients with spondyloarthritis. Scand. J. Rheumatol. 2020; 49 (6): 476–483. doi: 10.1080/03009742.2020.1751272

38. Kumthekar A., Ogdie A. Obesity and psoriatic arthritis : a narrative review. Rheumatol. Ther. 2020; 7 (3): 447e56. doi: 10.1007/s40744-020-00215-6

39. Bindesbøll C., Garrido-Cumbrera M., Bakland G. et al. Obesity increases disease activity of Norwegian patients with axial spondyloarthritis: results from the European map of axial spondyloarthritis survey. Curr. Rheumatol. Rep. 2020; 22(8): 43. doi: 10.1007/s11926-020-00917-4

40. Liew J. W., Huang I. J., Louden D. N. et al. Association of body mass index on disease activity in axial spondyloarthritis : systematic review and meta-analysis. RMD Open. 2020; 6 (1): e001225. doi: 10.1136/rmdopen-2020–001225

41. Ortolan A., Lorenzin M., Felicetti M. et al. Do obesity and overweight influence disease activity measures in axial spondyloarthritis? A systematic review and meta-analysis. Arthritis Care Res. 2021; 73 (12): 1815e25. doi: 10.1002/acr.24416

42. Walsh J. A., Wan M. T., Willinger C. et al. Measuring outcomes in psoriatic arthritis: comparing routine assessment of patient index data and psoriatic arthritis impact of disease. J. Rheumatol. 2020; 47 (10): 1496e505. doi: 10.3899/jrheum.190219

43. Garrido-Cumbrera M., Gálvez-Ruiz D., Delgado-Domínguez C.J. et al. Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. RMD Open. 2021; 7 (3): e001769. doi: 10.1136/rmdopen-2021–001769

44. Zhao S. S., Radner H., Siebert S. et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology. 2019; 58 (10): 1746e54. doi: 10.1093/rheumatology/kez119

45. Zhao S. S., Miller N., Harrison N. et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin. Rheumatol. 2020; 39 (1): 217e25. doi: 10.1007/s10067-019-04734-8

46. Zhao S. S., Jones G. T., Hughes D. M. et al. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology. 2021; 60 (12): 5734e42. doi: 10.1093/rheumatology/keab242

47. Cai M., Liu W., Wu Y. et al. The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis BMC Musculoskelet Disord. 2022; 23 (1): 717. doi: 10.1186/s12891-022-05657-3

48. Sargın B., Gurer G., Boztaş G. T., Ozturk H. Association between serum uric acid and inflammation markers in ankylosing spondylitis patients treated with tumor necrosis factor-α or nonsteroidal anti-inflammatory drugs. Eur. Res. J. 2019; 5 (1): 104–108. doi: 10.18621/eurj.359504

49. Lai Y., Zhang Y., Lei Z. et al. Association between serum uric acid concentration and radiographic axial spondylarthritis: a cross-sectional study of 202 patients. Chin. Med. J. 2023; 136: 1114–1116. doi: 10.1097/CM9.0000000000002148